One gene helps drive growth in two childhood brain tumor groups that lack targeted therapies

Targeting KDM2B or downstream protein complexes it recruits may exploit a vulnerability in high-risk medulloblastoma subgroups that currently lack targeted therapies, according to a study led by St. Jude Children's Research Hospital and Hopp Children's Cancer Center Heidelberg (KiTZ). The researchers found that Group 3 and Group 4 medulloblastomas depend on the protein KDM2B for growth and that removing it slowed tumor growth in preclinical models. The findings are published today in Nature Genetics.

Read it at Medical Xpress ↗

← Front page